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Blood flow changes in the optic nerve head of normal, adult albino rabbits following
intravenous administration of brovincamine fumarate (BV), an improver of cerebral
circulation and metabolism, were investigated employing the hydrogen clearance method.
In the BV (0.1 mg/kg)-administered group, the blood flow in the optic nerve head showed a
gradual increase immediately after injection and reached a maximal value of 124.2 ± 7.3%
against the value before injection at 20 min after injection, followed by a gradual decrease
in blood flow.  Statistical analysis showed a significant increase (P < 0.05) in blood flow at 10
to 40 min after injection, compared with the value before injection in the BV (0.1 mg/kg)-
administered group, but no significant changes in blood flow were observed in either the
BV (0.5 mg/kg)-administered group or the control group given no BV throughout the time
course.  No significant changes in the mean values of the mean blood pressure in the femoral
artery, pulse rate, respiratory rate or rectal temperature were observed in any group
throughout the experiment.  These results indicate the different efficacy of the two doses to
the relaxing action of the feeding vessels around the optic nerve head.
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Brovincamine is a compound in which brovine
is introduced at position 11 of vincamine, an
alkaloid extracted from vinca minor L.  Vinca-
mine has been reported to reduce vascular
resistance, leading to an increase in the cerebro-
vascular blood flow (Földi and Obál, 1965;
Solti, 1965; Noguchi et al., 1992).  Brovinca-
mine is also expected to produce vasodilation
through a blockade in the slow Ca2+-channel
(Katsuragi et al., 1984) and lead to an increase
in the cerebrovascular blood flow (Kushiku et
al., 1985). Brovincamine fumarate (BV,
Sabromin, Sandoz/Sankyo Pharmaceutical Co.,
Tokyo, Japan) (Fig.1) is used in Japan mainly as
an improver of cerebral circulation and metab-
olism, and also as an inhibitor of the aggrega-
tion of platelets through the cyclic AMP path-
way (Yasunaga, 1982).  This agent dilates intra-
cranial vessels more selectively than does
nifedipine, another Ca2+-channel blocker
(Katsuragi et al., 1984; Kushiku et al., 1985)
and seldom causes the adverse reactions induc-
ed by peripheral vasodilation, such as facial
flushing and orthostatic hypotension (Sawada
et al., 1996).  Recently, oral BV therapy has
been tried on patients with normal-tension
glaucoma (NTG), with favorable results in the
prevention of visual field defect progression
(Koseki et al., 1994; Sawada et al., 1996) and
the improvement of decreased retinal sensi-
tivity (Hama et al., 1992). BV has shown little
influence on the systemic blood pressure upon
administration unlike the other Ca2+-antago-
nists (Sugioka et al., 1982; Noguchi et al., 1992;
Abbreviations: BV, brovincamine fumarate; G, gauge; IOP, intraocular pressure; NTG, normal-tension
glaucoma; PG I2, prostaglandin I2
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Harino et al., 1992).  This is considered useful
for the treatment of patients with NTG, because
systemic hypotension is one of the risk factors
for glaucomatous damage to the optic nerve
head (Kaiser and Flammer, 1991; Kaiser et al.,
1993).  However, little is known about the influ-
ence of BV on the optic nerve head circulation
clinically or experimentally, although it is
known that the selective relaxing action of this
agent is most potent in isolated rabbit basilar
arteries (Narita et al., 1986).  In the present
study, therefore, the blood flow changes in the
optic nerve head of adult albino rabbits follow-
ing intravenous administration of BV were
investigated employing a hydrogen clearance
method which allows subsequent and repeated
measurements in vivo (Aukland et al., 1964).
Materials and Methods
Animals
The animal experiment reported here was done
in accordance with the Guidelines for Animal
Experiments at the Faculty of Medicine, Tottori
University.  We used 18 normal, adult albino
rabbits (18 eyes) of both sexes, each weighing
2.9 to 4.2 kg, for measurements of the blood
flow in the optic nerve head.  Anesthesia was
induced through an intramuscular injection of a
mixture of ketamine hydrochloride (40 to 60
mg/kg) and xylazine hydrochloride (2 to 3 mg/
kg).  Further anesthesia was maintained with 2
or 3 supplemental injections of pentobarbital
sodium (25 mg/kg; maximally 300 mg in total
volume) into the auricular vein.  Throughout the
experiment, the femoral artery was cannulated
with a catheter connected to a pressure
transducer to monitor the pulse rate and mean
blood pressure.  Further, the respiratory rate and
rectal temperature were measured routinely.
Measurements of blood flow in the optic
nerve head
Blood flow in the optic nerve head was measur-
ed according to the hydrogen clearance method
first reported by Aukland and others (1964), as
illustrated in Fig. 2. Each measurement was
performed by initially forcing the rabbit to
inhale 100% hydrogen gas (500 mL/min) with
room air for 30 to 40 s.  The decay curve, deriv-
ed from a UH meter (Unique Medical Co.,
Tokyo), was recorded on an A/D converter
(DR-F1, TEAC Corporation, Tokyo), then pro-
cessed as a logarithm with a computer (PC-
9801, NEC Corporation, Tokyo) to obtain the
half-decay time.  The absolute rate of blood
flow was derived from the half-decay time us-
ing the principles and methods of Kety and
Schmidt (1948).
According to our previously described
method (Hatta et al., 1993; Takahashi et al.,
1995), we used an epoxy resin-insulated plati-
num needle microelectrode of 100 µm in dia-
meter, which was inserted into a 27 gauge (G)
needle, for measuring the hydrogen concentra-
tion.  The active electrode was covered with a
vinyl tube except for the tip, the length of which
was 700 µm, equivalent to the insertion depth
(Figs. 2 and 3).  The microelectrode was in-
serted again into an 18 G needle and inserted
through the anterior sclera into the laminar por-
tion of the optic nerve head carefully, through a
contact lens of 60 diopters (Nippon Contact
Lens Ins., Nagoya, Japan) under an operation
microscope (Carl Zeiss Co., Tokyo) (Fig. 3).  A
silver-silver chloride wire was implanted under
the skin of the back as a reference electrode
(Fig. 2).
The anterior chamber was cannulated with a
21 G needle, which was connected to a reser-
voir filled with artificial aqueous equivalent
(Opeguard-MA, Senju Pharmaceutical Com-
pany, Osaka, Japan).  By controlling the height
of the reservoir (Fig. 3), the intraocular pressure
(IOP) level was maintained at 15 mmHg, which
Fig. 1.  Chemical structure of brovincamine fumarate.
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is regarded as normal in man and rabbit (Hatta
et al., 1993; Takahashi et al., 1995), throughout
the experiment.
Each rabbit in the BV (0.1 mg/kg)- and BV
(0.5 mg/kg)-administered groups (6 eyes out of
6 rabbits in each group) received the respective
dose of BV dissolved in physiological saline
solution (1 mL/kg) through the auricular vein
over about 1 min.  The control group (6 eyes out
of 6 rabbits) was given only the saline solution
(1 mL/kg).  The blood flow in the optic nerve
head was measured before and immediately
after the drug injection, then at intervals of 10
min.  The measurements were made on the left
eye of each rabbit in the 3 groups as illustrated
in Fig. 2.
The rabbit was killed by an intracardial
injection of pentobarbital sodium (about 50 mg/
kg) at the end of the experiment.  The eyeball
was removed and histological examination was
made using a light microscope (Olympus
Optical Co., Tokyo) to confirm the position of
the electrode and tissue damage.
Statistics
All values were expressed as mean ± SE.  Sta-
tistical analysis (Wilcoxon’s signed-ranks test)
was made between each data after the drug
administration and the data before the administ-
ration.  For multiple comparison, an analysis of
variance (ANOVA, Kruskal-Wallis test) and a
nonparametric analysis (Dunnett’s multiple
comparison procedure) were carried out among
multiple groups.  Values of P < 0.05 were con-
sidered statistically significant.
Results
Blood flow in the optic nerve head and
mean blood pressure in the femoral
artery before drug administration
The mean value of the blood flow in the optic
nerve head (from the surface of the optic nerve
head to 700 µm depth) before drug admin-
istration was 110.5 ± 13.4 mL/min/100 g (SE)
in the physiological saline solution (1 mL/kg)-
administered, control group, 128.1 ± 13.4 mL/
min/100 g in the BV (0.1 mg/kg)-administered
group and 109.1 ± 8.6 mL/min/100 g in the BV
(0.5 mg/kg)-administered group at the normal
IOP level of 15 mmHg.  There was no signifi-
cant difference in each mean value of the optic
nerve head blood flow among the 3 groups (6
eyes out of 6 rabbits in each group) according to
the Kruskal-Wallis test (Table 1).
The mean value of mean blood pressure in
the femoral artery before drug administration
was 90.3 ± 6.3 mmHg in the control group, 98.5
± 3.7 mmHg in the BV (0.1 mg/kg)-administered
Fig. 2.  Block diagram of the measurement of blood flow
with hydrogen gas in the optic nerve head.
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Fig. 3.  Schematic diagram of the micro-
electrode for measuring hydrogen concentration
and its insertion method.  The IOP level was
maintained at 15 mmHg by controlling the
height of the reservoir.  The electrode was cont-
rived to set the insertion depth at 700 µm.
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group and 101.2 ± 1.5 mmHg in the BV (0.5
mg/kg)-administered group.  There was no sig-
nificant difference in each mean value of the
mean femoral blood pressure among the 3
groups (6 rabbits in each group)  (Table 1).
Changes in blood flow in the optic nerve
head and in mean blood pressure in the
femoral artery throughout the experi-
ment
In the control group (Fig. 4), no
significant changes were observed in
either the mean value of the blood
flow in the optic nerve head or the
mean value of the mean blood pres-
sure in the femoral artery after ad-
ministration of physiological saline
solution (1 mL/kg), compared with
each corresponding data before ad-
ministration, which was estimated at
100% at the initial time in the present
study, throughout the time course by
Wilcoxon’s signed-ranks test.
In the BV (0.1 mg/kg)-administered
group (Fig. 5), the mean value of the
blood flow in the optic nerve head
showed a gradual increase imme-
diately after injection and reached the
maximal value of 156.5 ± 13.2 mL/
min/100 g corresponding to 124.2 ±
7.3% against the value before injec-
tion, at 20 min after injection, fol-
lowed by a gradual decrease in the
blood flow.  Statistical analysis show-
ed a significant increase (P < 0.05) in
blood flow at 10 to 40 min after in-
jection, compared with the initial
value before injection according to
Wilcoxon’s signed-ranks test, but no
significant changes were observed in
Table 1.  Blood flow in the optic nerve head and mean blood pressure in the femoral artery before
drug administration in the control, BV (0.1 mg/kg)- and BV (0.5 mg/kg)-administered groups
Control BV (0.1 mg/kg)- BV (0.5 mg/kg)- Kruskal-
 group* administered administered Wallis
group group test
Blood flow in the optic nerve head 110.5 ± 13.4 128.1 ± 13.4 l09.1 ± 8.8 NS
(mL/min/100 g)          [6]          [6]         [6]
Mean blood pressure in the femoral artery 90.3  ±   6.3   98.5 ±   3.7 l0l.2 ± 1.5 NS
(mmHg)          [6]          [6]         [6]
* The control group was given only physiological saline solution (1 mL/kg).
Values are expressed as mean ± SE.  [  ], number of animals (eyes) examined.
BV, brovincamine fumarate; NS, not significant (P > 0.05).
Fig. 4.  Changes in blood flow in the optic nerve head and in
the mean blood pressure in the femoral artery in the physio-
logical saline solution (1 mL/kg)-administered, control group.
Vertical bars indicate SE of the mean; n, number of animals
(eyes) examined.  No significant changes are observed in
either the mean value of the optic nerve head blood flow or the
mean value of the mean femoral blood pressure, compared
with each corresponding data before administration, which
was estimated at 100% at the initial time (0), according to
Wilcoxon’s signed-ranks test (P > 0.05).
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the mean value of mean blood pressure
in the femoral artery throughout the ex-
periment.
In the BV (0.5 mg/kg)-administered
group (Fig. 6), no significant changes
were observed in either the mean value
of the blood flow in the optic nerve
head or the mean value of mean blood
pressure in the femoral artery after
injection, compared with each corres-
ponding data before injection through-
out the time course according to
Wilcoxon’s signed-ranks test.
An analysis of variance made with
the Kruskal-Wallis test showed signi-
ficant P values at 10 to 40 min after
drug administration (0.0233 at 10 min,
0.0034 at 20 min, 0.0189 at 30 min and
0.0278 at 40 min) in the comparison of
blood flow changes in the optic nerve
head in the control, BV (0.1 mg/kg)-
and BV (0.5 mg/kg)-administered
groups (Table 2).  In the multiple
comparison of the blood flow in the
optic nerve head at 10, 20, 30 and 40
min after drug administration in the 3
groups, Dunnett’s multiple comparison
procedure showed significant increases
in optic nerve head blood flow at 20 to
40 min after injection (P < 0.01 at 20
min, P < 0.05 at 30 min and P < 0.05 at
40 min) in the BV (0.1 mg/kg)-
administered group, compared with the
corresponding data in the control group
(Table 3).
Fig. 5.  Changes in blood flow in the optic nerve head and in
the mean blood pressure in the femoral artery in the
brovincamine fumarate (0.1 mg/kg)-administered group.
Vertical bars indicate SE of the mean; n, number of animals
(eyes) examined. Statistical analysis shows a significant
increase in the mean value of the optic nerve head blood
flow at 10 to 40 min after injection [*P < 0.05 compared
with the corresponding data before administration, which
was estimated at 100% at the initial time (0), according to
Wilcoxon’s signed-ranks test].  No significant changes are
observed in the mean value of the mean femoral blood
pressure throughout the experiment.
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Fig. 6.  Changes in blood flow in the optic
nerve head and in the mean blood pressure in
the femoral artery in the brovincamine fuma-
rate (0.5 mg/kg)-administered group.  Verti-
cal bars indicate SE of the mean;  n, number
of animals (eyes) examined.  No significant
changes are observed in either the mean value
of the optic nerve head blood flow or the
mean value of the mean femoral blood
pressure, compared with each corresponding
data before administration, which was esti-
mated at 100% at the initial time (0), by
Wilcoxon’s signed-ranks test (P > 0.05). Time
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Changes in the pulse rate, respiratory
rate and rectal temperature before and
after drug administration
Statistical analyses carried out by the Kruskal-
Wallis test and Wilcoxon’s signed-ranks test
showed no significant changes in the mean
values of the pulse rate, respiratory rate or rectal
temperature in any group through the
experiment (Table 4).
Histological findings
It was confirmed by the light microscope that
the position of the microelectrode for measur-
ing the hydrogen concentration was almost at
the center of the optic nerve head. No remark-
able tissue damage or hemorrhage was observ-
ed due to the fine 100 µm microelectrode used
in this test (Fig. 7).
Discussion
The hydrogen clearance method used in the
present study is called the most useful technique in
investigating microcirculation (Aukland et al.,
1964; Hatta et al., 1993; Takahashi et al., 1995).
In this study, the mean value of blood flow in
the laminar portion of the optic nerve head
before drug administration was 110.5 ± 13.4
mL/min/100 g in the control group, 128.1 ±
13.4 mL/min/100 g in the BV (0.1 mg/kg)-
administered group and 109.1±8.6 mL/min/100
g in the BV (0.5 mg/kg)-administered group at
the normal IOP level of 15 mmHg.  Although
variance without statistical significance was ob-
served in each mean value among the 3 groups,
these values were almost similar to previously
reported mean blood flow rates in the laminar
portion of the optic nerve head in normal, adult
albino rabbits employing the clearance method
at the IOP level of 15 mmHg; 119.3 ± 7.9 mL/
min/100 g (Hatta et al., 1993) and 116.6 ± 7.7
mL/min/100 g (Takahashi et al., 1995).  These
data indicate little difference in the optic nerve
head blood flow among the experimental rab-
bits with a normal IOP level.
In the present study, BV was administered
through the auricular vein in rabbits at dosages
of 0.1 mg/kg and 0.5 mg/kg.  There have been
no reports on pharmacokinetics in plasma in
rabbits after intravenous administration of the
agent.  Thus the lower and the higher doses for
Table 2. Comparison of blood flow changes in the optic nerve head after drug administration
in the control, BV (0.1 mg/kg)- and BV (0.5 mg/kg)-administered groups (Kruskal-Wallis test)
     Time (min)
Immediately 10 20 30 40 50 60 70 80 90 100
 after
P value NS 0.0233 0.0034 0.0189 0.0278 NS NS NS NS NS NS
Group given no BV served as the control.
BV, brovincamine fumarate; NS, not significant (P > 0.05) (number of eyes examined: 6 eyes in each group).
Table 3 . Multiple comparison of blood flow in the optic nerve head at 10, 20, 30 and 40 min
after drug administration in the control, BV (0.1 mg/kg)- and BV (0.5 mg/kg)-administered
groups (Dunnett’s multiple comparison procedure)
                         Control group*
10 min 20 min 30 min  40 min
BV (0.1 mg/kg)-administered group NS P < 0.01 P < 0.05 P < 0.05
BV (0.5 mg/kg)-administered group NS  NS NS NS
* The control group was given only physiological saline solution (1 mL/kg).
BV, brovincamine fumarate; NS, not significant (P > 0.05) (number of eyes examined: 6 eyes in each
group).
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intravenous use in rabbits were determined re-
ferring to the minimal single dose for intra-
venous use in humans (about 0.2 mg/kg); this
intravenous single dose was estimated to be
Table 4. Changes in the pulse rate, respiratory rate and rectal temperature before and after
drug administration in the control, BV (0.1 mg/kg)- and BV (0.5 mg/kg)-administered groups
Before Immediately 10 min 20 min 30 min 60 min 100 min
after
Control group*
    Pulse rate 255 ± 11 252 ± 10 253 ± 11 252 ± 11 257 ± 11 262 ± 12 274 ± 8
(/min)
    Respiratory rate   54 ±   8   55 ±  9   52 ±   9   51 ±   9   47 ±   5   51 ±   9   41 ± 6
(/min)
    Rectal temperature   38.8± 0.6     ND     ND   38.8± 0.6   38.8± 0.6   38.6± 0.6   38.3±0.6
(˚C)
BV (0.1 mg/kg)-administered group
    Pulse rate 262 ±   7 260 ± 7 259 ± 1  262 ± 12 257 ± 10 254 ± 10 255 ± 10
(/min)
    Respiratory rate   47 ±   3   46 ± 4   45 ± 4    43 ±   4   43 ±   5   43 ±   5   48 ±   4
(/min)
    Rectal temperature   38.5± 1.1     ND     ND    38.5± 1.1   38.5± 1.1   38.4± 1.2   39.2± 1.3
(˚C)
BV (0.5 mg/kg)-administered group
    Pulse rate 268 ±   8 259 ± 7 266 ± 8 267 ±  8 264 ±  6 266 ±  5 268 ±  8
(/min)
    Respiratory rate   43 ±   3   42 ± 3   42 ± 4   42 ±  3   42 ±  3   39 ±  3   37 ±  3
(/min)
    Rectal temperature   38.3±0.5      ND    ND   38.1±0.6   38.1±0.6   38.1±0.6   37.7±1.0
(˚C)
* The control group was given only physiological saline solution (1 mL/kg).
Values are expressed as mean ± SE (number of animals examined: 6 rabbits in each group).
BV, brovincamine fumarate; ND, no available data.
Fig. 7.  Light micrograph showing the site of
insertion of the microelectrode.  An arrow indicates
the position (hematoxylin and eosin).  Bar = 1 mm.
equivalent to the oral single dose, which reach-
es maximal plasma concentration in 60 min
after oral administration in humans (0.3 mg/kg)
(Mayo et al., 1982).
The perfusion pressure of optic nerve head
circulation is regarded as the gap between blood
pressure and IOP.  The mean blood pressure in
the femoral artery is adopted as the standard
blood pressure in our experiments, although,
ideally, the mean blood pressure in the ciliary
artery, which is about 16 mmHg lower than that
in the femoral artery in rabbits (Bill, 1963),
should be employed.
In rabbits, autoregulation, which is defined
as an autoregulatory function to maintain blood
flow by changing vessel resistance when the
perfusion pressure decreases (Ojima, 1989), is
weak in the optic nerve head (Hatta et al.,
M. Tonomoto et al.
96
analogue, produced a dose-dependent relaxa-
tion in monkey isolated cerebral arteries; the
higher concentration of isocarbacyclin elicited
a transient contraction which is probably induc-
ed through the activation of thromboxane A2
receptors.  A similar mechanism may act even
in the case of BV administration.
Furthermore, BV acts as an inhibitor of
platelet aggregation through the cyclic AMP
pathway (Yasunaga, 1982), as described above.
Accordingly, further studies are needed to
elucidate the mechanism of the different
efficacy of the two doses in light of the cyclic
AMP changes in the arterial smooth muscles
induced by BV administration, or in light of the
receptor responsiveness to drug concentration,
besides the action through the blockade of the
slow Ca2+-channel (Katsuragi et al., 1984), be-
cause there is a regional difference in the BV-
induced relaxation of the smooth muscles in the
rabbit arteries (Narita et al., 1986).
Concerning oral BV therapy for patients
with NTG, the lower dose administration of BV
furnishes us with the useful suggestion that its
potent vasodilation effects in rabbits should
improve the optic nerve head blood flow even
when orally administered in humans, helping
the nerve maintain its integrity more potentially
and resulting in favorable results (Hama et al.,
1992; Koseki et al., 1994; Sawada et al., 1996),
although the therapeutic value of a higher dose
of orally administered BV in eyes with NTG
remains to be elucidated clinically.
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